HA was grafted onto metformin-loaded GO nanoparticles as a CD44-targeted anti-cancer therapy for triple-negative breast cancer, which exhibited anti-cancer efficacy at a much lower dosage as compared with metformin alone [185]. Here, CD44 is linked to triple-negative breast carcinoma.